MALAT1 and prostate carcinoma: Collectively, our results provide compelling evidence that MALAT1 depletion enhances the sensitivity to PARPi; hence, targeting both simultaneously will be a promising therapeutic approach for patients with advanced stage prostate cancer, who often develop resistance to conventional therapeutic strategies.